Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENITH20 phase 2 study of poziotinib in advanced NSCLC with EGFR or HER2 exon 20 mutations
MOH_2019-05-29_007145Phase 2Recruiting
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of poziotinib in non-small cell lung cancer (NSCLC) (7 arms), sponsored by Spectrum Pharmaceuticals, Inc. Started Apr 2019; status: recruiting.
02
Drugs
poziotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2019-05-29_007145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-29_007145.